MX2020007555A - Anticuerpos potenciadores del factor h y usos de los mismos. - Google Patents

Anticuerpos potenciadores del factor h y usos de los mismos.

Info

Publication number
MX2020007555A
MX2020007555A MX2020007555A MX2020007555A MX2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A
Authority
MX
Mexico
Prior art keywords
factor
antibodies
fragments
potentiating antibodies
complement activation
Prior art date
Application number
MX2020007555A
Other languages
English (en)
Inventor
Taco Willem Kuijpers
Diana Wouters
Maria Clara Brouwer
Richard Benjamin Pouw
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Publication of MX2020007555A publication Critical patent/MX2020007555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a nuevos anticuerpos aislados, sintéticos o recombinantes y fragmentos de los mismos específicos para el Factor H. La invención se refiere además al uso de tales anticuerpos y fragmentos para inhibir la activación del complemento y el tratamiento de trastornos asociados con la activación del complemento.
MX2020007555A 2018-01-15 2019-01-15 Anticuerpos potenciadores del factor h y usos de los mismos. MX2020007555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18151726 2018-01-15
PCT/NL2019/050018 WO2019139481A1 (en) 2018-01-15 2019-01-15 Factor h potentiating antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020007555A true MX2020007555A (es) 2021-01-15

Family

ID=60972152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007555A MX2020007555A (es) 2018-01-15 2019-01-15 Anticuerpos potenciadores del factor h y usos de los mismos.

Country Status (11)

Country Link
US (2) US11377487B2 (es)
EP (1) EP3740502A1 (es)
JP (2) JP7471224B2 (es)
KR (2) KR20250171487A (es)
CN (1) CN111868083B (es)
AU (1) AU2019206207B2 (es)
BR (1) BR112020014399A2 (es)
CA (1) CA3088507A1 (es)
IL (1) IL276008A (es)
MX (1) MX2020007555A (es)
WO (1) WO2019139481A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740502A1 (en) * 2018-01-15 2020-11-25 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
AR122286A1 (es) * 2019-07-17 2022-08-31 Gemini Therapeutics Sub Inc Anticuerpos potenciadores del factor h y usos de estos
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
WO2023009759A2 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof
CN116355860A (zh) * 2021-12-28 2023-06-30 四川远大蜀阳药业有限责任公司 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用
CN116655792B (zh) * 2022-03-21 2024-01-02 南京蓬勃生物科技有限公司 靶向Siglec-15的单克隆抗体及其应用
NL2032398B1 (en) * 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
CN118878671B (zh) * 2024-07-04 2025-09-30 南京农业大学 抗兽疫链球菌SzM蛋白的猪源化单克隆抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2826883T3 (es) * 2009-10-14 2021-05-19 Janssen Biotech Inc Métodos de maduración por afinidad de anticuerpos
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
MX378112B (es) * 2014-08-20 2025-03-10 Stichting Sanquin Bloedvoorziening Anticuerpos que potencian el factor h y sus usos.
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
EP3740502A1 (en) * 2018-01-15 2020-11-25 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
AR122286A1 (es) * 2019-07-17 2022-08-31 Gemini Therapeutics Sub Inc Anticuerpos potenciadores del factor h y usos de estos

Also Published As

Publication number Publication date
JP2023089191A (ja) 2023-06-27
JP7471224B2 (ja) 2024-04-19
JP2021510523A (ja) 2021-04-30
CN111868083A (zh) 2020-10-30
IL276008A (en) 2020-08-31
US20220356235A1 (en) 2022-11-10
CN111868083B (zh) 2025-02-11
KR20200110688A (ko) 2020-09-24
AU2019206207A1 (en) 2020-08-13
CA3088507A1 (en) 2019-07-18
US20210054059A1 (en) 2021-02-25
US11377487B2 (en) 2022-07-05
KR20250171487A (ko) 2025-12-08
BR112020014399A2 (pt) 2020-12-29
WO2019139481A1 (en) 2019-07-18
KR102896085B1 (ko) 2025-12-08
AU2019206207B2 (en) 2025-04-10
EP3740502A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2020003190A (es) Degradadores de proteinas y usos de los mismos.
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018501525A1 (en) Tgfbeta 2 antibodies
PH12022551228A1 (en) Trem2 antibodies and uses thereof
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12020550023A1 (en) Compositions for treating stress-related disorders
PH12018502275B1 (en) Interferon beta antibodies and uses thereof
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
ZA202006216B (en) Antibodies targeting glycoprotein vi
MX390865B (es) Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2020010092A (es) Variantes de anticuerpo c-terminales.
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
MX2022000725A (es) Anticuerpos potenciadores del factor h y usos de estos.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders